Diagnostics, Telemedicine. Company provides surface protein technology that enhances the utility of diagnostic applications, via the integration of biological analysis and wireless technology. It is currently developing a miniature wireless platform enabling the reading of biological samples (i.e., swabs, blood tests), and subsequent forwarding of results to physicians via mobile phone. The company expects its device to significantly reduce the time between diagnosis and treatment upon its market release (anticipated in 2014). It presents opportunities in the biosensors market (expected to reach $6.1 billion in 2012) and in the telemedicine sector (projected to reach $7.7 billion by 2012). Founded: 2001, Employees: 6.